Search

Oryzon Genomics, S.A., the Spanish company developing innovative epigenetic experimental therapies, announces results and progress in the first half of 2021

The company announced the launch of a new antibody test that detects three types of antibodies against four proteins of the SARS-CoV-2 virus with a single blood sample and 99% of reliability

The robot facilitates thyroid diagnosis by interacting with humans and making an assessment based on preset parameters

The new ePILOT bioreactors, ranging from 10 to 50 litres in useful volume, feature an extremely compact design ideal for tight spaces.

Laboratorios Rubio S.A has submitted to the FDA all the documentation for the registry of 2 blood sample based diagnostic tests, as first step with its international expansion strategy

Biocompanies are synonymous of innovation and transformation, as they have always outlined each area of their activity in order to concentrate talent, new technologies and research

AlmirallShare, the company’s R&D open innovation platform, and looks for partnering opportunities for new assets in order to offer breakthrough innovation and accelerate the generation of new

This European recommendation has validated the use of this technology to produce recombinant biologics and biocomponents

With the data obtained in the targeted literature, a cost-of-illness model has been developed to determine the cost of thalassaemia

3P Biopharmaceuticals operates globally, with 19 active projects worldwide and has positioned itself, after a difficult start in 2006, as a leader in the biologics manufacturing field in Spain

GENESIS Biomed has participated in the preparation of the THINK TANK report "Patenting and/or publishing" by the FECYT, which covers the debate on publishing research or its transfer and exploitation

Precision medicine and personalised medicine products or services have gone from representing 12% of total launches to 52% in 2020. Navarra, which is hosting Biospain 2021, is one of the pioneering

Clinical Trial Application approved by Spanish Drug Agency Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Second Phase IIb study of

Vafidemstat was safe and well tolerated Confirmed anti-inflammatory activity of vafidemstat Vafidemstat reduced exacerbated CD4+ T cell activation and inflammatory cytokine release Fast recovery of

The investment round is led by Clave Capital, counting with investment from CDTI through its Innvierte program and the support from Genesis Biomed

This is a major achievement for Ysios as CVRx is its fifth portfolio company to be listed on NASDAQ, and the second within just three months.

El IVDR evolucionó a partir de la IVDD para establecer un “marco más sólido, transparente, predecible y sostenible para los IVDs”

Biotech companies launched 70% more products and services to market and Spain moved to eighth in the world in scientific production in biotechnology